Clinical trial registry record

Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 1 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated September 21, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT07162038
Last registry update
September 21, 2026
Status
Recruiting
Phase
Phase 1
Sponsor
National Cancer Institute (NCI)
Enrollment
155
Countries
United States
Match confidence
62%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 1
Study design
NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
155
Population
ALL · 18 Years to 75 Years
Duration
2025-11-14 to 2034-10-01
Intervention
mCD19-CAR-CD28-CD3-zeta.(anti-CD19 CAR) retroviral vector-transduced allogeneic peripheral blood lymphocytes (PBL); Fludarabine; Cyclophosphamide; Mycophenolate Mofetil; Sirolimus; CD19 Flow Cytometry Assay; CD19 Immunohistochemical Assay; Total Body Irradiation
Comparator
Donor
Outcomes measured
Identify the safety of anti-CD19 CAR T-cell therapy in combination with HLA-haploidentical HCT in participants with hig…; Estimate the 1 year relapse and survival outcomes at the maximum tolerated dose — 1 year; Estimate the incidence and severity of CRS and ICANS — 100 days; Estimate the incidence of Grade II-IV and Grade III-IV acute GVHD at +200 days — 200 days; Estimate the incidence and severity of chronic GVHD at 1 year — 1 year; Estimate incidence of primary engraftment failure and kinetics of engraftment — 60 days; Estimate relapse/progression, non-relapse mortality, progression-free survival, and overall survival at 1 year — 1 year; Estimate relapse/progression, non-relapse mortality, progression-free survival, and overall survival at 5 years — 1 year
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 1A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 62% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 62%Source terminology contains a controlled topic term. Summary supplies ageing or longevity context.

Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON